Management Team

Group Offshore Holding Structure

Group Business Structure

Industrial Chain & Global Footprint
Taiwan: Integrated R&D and Full Value Chain

  • Industry-Academia Research Laboratory: 

  • Strain Bank / Culture Collection Center

  • Patented Carriers

  • Cultivation Facility

  • End-Consumer Brands

  • Product Processing & Manufacturing

  • Supply Chain Management

Mainland China: Strategic R&D and Planned Expansion

  • Strain R&D Technical Center

  • Standardized Cultivation Demonstration Facility

  • Under Development / Pipeline: 

    • Self-Operated Cultivation Facility

    • Collaborative Cultivation Facility

    • Supply Chain & Trading Company

MANAGEMENT TEAM

C.S. Group is a Cayman Islands–incorporated holding company focused on rare and high-value medicinal fungi. Our leadership team brings a strong combination of expertise across cultivation science, bioactive extraction and drug development, academic research, wellness product commercialization, and brand-building and marketing—enabling us to bridge innovation from the lab to scalable market impact.

Dalan Huang
Chairman & CEO

Chairman Dalan Huang brings nearly 20 years of extensive experience in business development and executive management within the healthcare and supplement markets across the Greater China region, supported by a robust professional network. At Cordyceps Sunshine Biotech Holdings Co., Ltd. (C.S. Group), he is responsible for overseeing internal operations and spearheading external market expansion.

From May 2018 to May 2020, Mr. Huang served as Vice President of the Overseas Business Division for a prominent Chinese asset management firm, where he led international market growth initiatives. Prior to that, from January 2015 to January 2018, he held the position of Chief Executive Officer at a Taiwanese biomedical company. During his tenure as CEO, he orchestrated the company’s global expansion and led the R&D of the “Smart Hydrogen-Rich Water Purification System.” This innovative product secured patents in Germany, Japan, China, and Taiwan, and was honored with seven invention awards across the world’s four major invention exhibitions in 2015 and 2016.

From November 2013 to November 2014, Mr. Huang served as General Manager of a well-known Taiwanese functional beverage brand, where he was responsible for defining operational strategies and driving marketing initiatives.

Vincent Liu
CTO & CEO of Drug Development Center

CTO Vincent Liu possesses extensive expertise in the cultivation of rare medicinal fungi and the execution of large-scale extraction processes. Within the Group, he leads the core technical divisions, focusing on strain development, bioactive compound extraction, and the implementation of pharmaceutical R&D experiments.

Since June 2020, Mr. Liu has served as the Chief Technology Officer of C.S. Group. During his tenure, he was instrumental in securing patents across Taiwan, China, Japan, and the United States for the Group’s proprietary technology: “Method for Cultivating Taiwanofungus camphoratus and Porous Cultivation Carriers.”

From July 2017 to June 2020, he served as a Technical Consultant for a Taiwanese biomedical firm. Previously, from May 2014 to July 2017, he held the position of General Manager at a Taiwanese biotechnology company, where he was primarily responsible for the R&D of innovative biochemical technologies. Earlier in his career, Mr. Liu served as a Manager at a biotech firm in Taiwan, overseeing the R&D and production of herbal products imported from India.